# Biotech Daily Digest — 2025-10-11

**11 items from 3 sources**

## Summary by Source

- Eli Lilly Press Releases: 3 items
- Endpoints News: 5 items
- Fierce Biotech: 3 items


## Eli Lilly Press Releases

- **[Lilly plans to expand Purdue University collaboration with up to a $250 million investment to accelerate pharmaceutical innovation](https://investor.lilly.com/news-releases/news-release-details/lilly-plans-expand-purdue-university-collaboration-250-million)**  
  _Fri, 09 May 2025 08:00:00 -0400_  
  INDIANAPOLIS and WEST LAFAYETTE, Ind. , May 9, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Purdue University announced today a significant expansion of their long-standing alliance, with Lilly's planned investment of up to $250 million in the collaboration over the next eight years.

- **[Lilly announces transitions in executive leadership](https://investor.lilly.com/news-releases/news-release-details/lilly-announces-transitions-executive-leadership)**  
  _Thu, 08 May 2025 06:45:00 -0400_  
  INDIANAPOLIS , May 8, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced executive leadership transitions that will further enhance the company's ability to drive sustained, long-term growth and ensure that its medicines continue to reach millions of people worldwide.

- **[Statement: Lilly has no affiliation with hims & hers](https://investor.lilly.com/news-releases/news-release-details/statement-lilly-has-no-affiliation-hims-hers)**  
  _Tue, 01 Apr 2025 17:00:00 -0400_  
  INDIANAPOLIS, April 1, 2025 – Eli Lilly and Company (NYSE: LLY) has no affiliation with hims & hers. Zepbound (tirzepatide) can be prescribed by any licensed healthcare professional. People who are commercially insured with coverage for Zepbound may be eligible to pay as low as $25.


## Endpoints News

- **[Meet this year’s Women in Biopharma; Peter Marks goes to Eli Lilly; Bob Langer startup launches; and more](https://endpoints.news/meet-this-years-women-in-biopharma-peter-marks-goes-to-eli-lilly-bob-langer-startup-launches-and-more/)**  
  _Sat, 11 Oct 2025 10:00:36 +0000_  
  Willkommen, bienvenue, welcome back to another edition of Endpoints Weekly. We’re supposed to get a Nor’easter this weekend on the East Coast after a mostly dry summer. The rain is needed, but hopefully everyone can ...

- **[AstraZeneca strikes pricing deal with Trump](https://endpoints.news/astrazeneca-strikes-pricing-deal-with-trump/)**  
  _Fri, 10 Oct 2025 22:21:21 +0000_  
  British pharma AstraZeneca has reached a drug pricing deal with the Trump administration, agreeing to similar discounts across its portfolio to what Pfizer signed onto last week.

 Under the deal unveiled Friday evening at the ...

- **[New study suggests patients with anti-AAV antibodies may still receive gene therapy](https://endpoints.news/new-study-suggests-patients-with-anti-aav-antibodies-may-still-receive-gene-therapy/)**  
  _Fri, 10 Oct 2025 18:47:55 +0000_  
  SEVILLE, SPAIN — Gene therapies are offering new hope to some patients with rare disease, but not everyone. A third or more of patients are often turned away because they've already been infected with natural versions ...

- **[White House, AstraZeneca expected to announce drug price deal](https://endpoints.news/white-house-astrazeneca-expected-to-announce-drug-price-deal-msnbc/)**  
  _Fri, 10 Oct 2025 16:51:36 +0000_  
  The White House and AstraZeneca are expected to announce a deal on drug pricing later Friday, according to people familiar with the matter, as President Donald Trump strikes a second agreement under his "most favored ...

- **[Biopharma is wagering billions of dollars that CAR-T therapy can be easier. Will it work this time?](https://endpoints.news/biopharma-is-wagering-billions-of-dollars-that-car-t-therapy-can-be-easier-will-it-work-this-time/)**  
  _Fri, 10 Oct 2025 15:37:23 +0000_  
  Large biopharma companies have spent over $4 billion in 2025 to buy startups working on in vivo CAR-T therapies as the first data in humans emerge.

 While it's still early days for in vivo cell ...


## Fierce Biotech

- **[<a href="https://www.fiercebiotech.com/biotech/novo-shutters-cell-therapy-unit-ending-work-potential-type-1-diabetes-cure" hreflang="en">Novo shutters cell therapy unit, ending work on potential Type 1 diabetes 'cure'</a>](https://www.fiercebiotech.com/biotech/novo-shutters-cell-therapy-unit-ending-work-potential-type-1-diabetes-cure)**  
  _Oct 10, 2025 3:02pm_  
  Novo Nordisk is ending all work in cell therapy, including a Type 1 diabetes program, amid CEO Maziar Mike Doustdar's reorganization. As part of the move, the company is laying off nearly all of the division’s 250 employees, according to a Danish publication.

- **[<a href="https://www.fiercebiotech.com/biotech/jj-talks-pen-new-chapter-protagonist-partnership-buyout-wsj" hreflang="en">J&amp;J in talks to buy immunology partner Protagonist: WSJ </a>](https://www.fiercebiotech.com/biotech/jj-talks-pen-new-chapter-protagonist-partnership-buyout-wsj)**  
  _Oct 10, 2025 2:14pm_  
  Johnson & Johnson may be looking to deepen its relationship with immunology partner Protagonist Therapeutics with a takeover deal, The Wall Street Journal reports.

- **[<a href="https://www.fiercebiotech.com/biotech/cabalettas-car-t-therapy-wipes-out-b-cells-small-autoimmune-trial-without-preconditioning" hreflang="en">Cabaletta CAR-T wipes out B cells without preconditioning in small autoimmune trial</a>](https://www.fiercebiotech.com/biotech/cabalettas-car-t-therapy-wipes-out-b-cells-small-autoimmune-trial-without-preconditioning)**  
  _Oct 10, 2025 10:36am_  
  Cabaletta Bio’s CAR-T cell therapy successfully eliminated the overreactive B cells of two patients with an autoimmune disease, even without any preconditioning chemotherapy, pleasing investors and analysts alike and providing hope of less toxic autoimmune treatments.
